Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • US Panel Backs...

    US Panel Backs Approval For Merck Infectious Diarrhea Drug

    Written by savita thakur thakur Published On 2016-06-12T16:14:24+05:30  |  Updated On 12 Jun 2016 4:14 PM IST
    US Panel Backs Approval For Merck Infectious Diarrhea Drug

    Merck & Co's experimental drug to treat the most common cause of hospital associated infectious diarrhea warrants approval, an advisory panel to the U.S. Food and Drug Administration said on Thursday.


    The panel voted 10-5, with one abstention, that the drug, bezlotoxumab, was effective in preventing a recurrence of infection with Clostridium difficile, or C. difficile, a germ that causes inflammation of the colon and potentially fatal diarrhea.


    The FDA is not obliged to follow the advice of its advisory panels but typically does.


    The panel's vote follows an internal review by FDA staff which found an apparent decrease in recurrence of C. difficile but expressed concern as to whether the drug could hurt the cure rate of the initial C. difficile episode.


    Panelists who voted in favor of the drug acknowledged the FDA's concerns but said they were persuaded there was a need for new targeted therapies and this one seems effective.


    "We haven't had a new drug for C. difficile in our armamentarium for some time," Dr. Joanna Schaenman, assistant professor of medicine at UCLA David Geffen School of Medicine, said.


    Spores from C. difficile bacteria cling to surfaces and can spread easily in hospitals and nursing homes. The germ infected nearly 500,000 people in 2011 and killed 15,000, according to the Centers for Disease Control.


    C. difficile is typically treated with antibiotics. But these kill good bacteria in the gut, setting up a vicious cycle in which low levels of good bacteria make it more difficult for the body to fend off the bad C. difficile germ.


    Bezlotoxumab is designed to neutralize C. difficile toxin B, suppressing symptoms long enough for the body's natural flora to replenish and preventing the need for additional cycles of antibiotics.


    Still, not all panelists were convinced, saying the drug had been tested on too few people to be sure it was really helping achieve a sustained cure, and they worry the drug could even impede a cure.


    Dr. Lindsey Baden, director of clinical research at Brigham and Women's Hospital and the panel's acting chair, said the drug was promising but so far, "the level of proof is not there yet."


    The FDA is due to make its decision by July 23.


    (Reporting by Toni Clarke in Washington; Editing by David Gregorio and Matthew Lewis)

    Brigham and Women's HospitalDavid Gregoriodiarrheadiarrhea drugDr Joanna SchaenmanDr Lindsey BadenMatthew LewisToni ClarkeUCLA David Geffen School of MedicineUS Food & Drug AdministrationUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok